- $295.44m
- $248.63m
- $142.52m
- 93
- 59
- 81
- 92
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | 20-F | 20-F |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 127 | 133 | 104 | 129 | 143 |
Cost of Revenue | |||||
Gross Profit | 49.7 | 47.6 | 30.3 | 46.7 | 55.5 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 104 | 114 | 104 | 125 | 132 |
Operating Profit | 22.8 | 19.2 | -0.696 | 4.53 | 10.1 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 23 | 18.6 | -1.89 | -2.26 | 8.43 |
Provision for Income Taxes | |||||
Net Income After Taxes | 22.3 | 17.1 | -2.23 | -2.32 | 8.28 |
Net Income Before Extraordinary Items | |||||
Net Income | 22.3 | 17.1 | -2.23 | -2.32 | 8.28 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 22.3 | 17.1 | -2.23 | -2.32 | 8.28 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.548 | 0.384 | -0.05 | -0.052 | 0.154 |
Dividends per Share |